Ni Ai1, Richard D Wood2, Eric Yang2, William J Welsh3. 1. Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang, 310058, People's Republic of China. 2. Snowdon, Inc., Princeton, New Jersey, 08540, USA. 3. Department of Pharmacology, Rutgers-Robert Wood Johnson Medical School, Rutgers University, 661 Hoes Lane West, Staged Research Building (room SRB-124), Piscataway, New Jersey, 08854, USA. welshwj@rwjms.rutgers.edu.
Abstract
PURPOSE: Novel therapeutics are greatly needed that target specific pathological receptors and pathways involved in Neuropathic Pain (NP). Extending our previous work published in this Journal on Group I metabotropic glutamate receptor (mGluR) modulators, we now investigate the therapeutic potential of niclosamide in modulating aberrant glutamate transmission in NP. METHOD: Calcium mobilization assays and cross-receptor selectivity experiments are conducted to characterize the pharmacological activity of niclosamide. A focused series of niclosamide analogues is then prepared to elucidate key structural determinants that emerged from computational molecular modeling analysis on drug-receptor interactions. Finally, niclosamide and a carbamate derivative are studied to assess their efficacy in an NP-evoked mechanical hyperalgesia model in rats. RESULTS: Niclosamide is a low-nanomolar allosteric antagonist of Group I mGluRs with high selectivity for Group I over homologous Group III mGluRs. The phenolic hydroxyl group of niclosamide forms a crucial hydrogen bond with mGluR1/5. Its bioactive coplanar conformation is further stabilized by the nitro substituent on the B ring and an intramolecular bond. Mechanical hyperalgesia in NP rats is reversed by niclosamide through three different dosing routes. CONCLUSION: To our knowledge, this is the first report of the salicylanilide class of compounds as potential treatments for NP.
PURPOSE: Novel therapeutics are greatly needed that target specific pathological receptors and pathways involved in Neuropathic Pain (NP). Extending our previous work published in this Journal on Group I metabotropic glutamate receptor (mGluR) modulators, we now investigate the therapeutic potential of niclosamide in modulating aberrant glutamate transmission in NP. METHOD:Calcium mobilization assays and cross-receptor selectivity experiments are conducted to characterize the pharmacological activity of niclosamide. A focused series of niclosamide analogues is then prepared to elucidate key structural determinants that emerged from computational molecular modeling analysis on drug-receptor interactions. Finally, niclosamide and a carbamate derivative are studied to assess their efficacy in an NP-evoked mechanical hyperalgesia model in rats. RESULTS:Niclosamide is a low-nanomolar allosteric antagonist of Group I mGluRs with high selectivity for Group I over homologous Group III mGluRs. The phenolic hydroxyl group of niclosamide forms a crucial hydrogen bond with mGluR1/5. Its bioactive coplanar conformation is further stabilized by the nitro substituent on the B ring and an intramolecular bond. Mechanical hyperalgesia in NP rats is reversed by niclosamide through three different dosing routes. CONCLUSION: To our knowledge, this is the first report of the salicylanilide class of compounds as potential treatments for NP.
Entities:
Keywords:
group I metabotropic glutamate receptors; neuropathic pain; niclosamide
Authors: Filippo Caraci; Gemma Molinaro; Giuseppe Battaglia; Maria Laura Giuffrida; Barbara Riozzi; Anna Traficante; Valeria Bruno; Milena Cannella; Sara Merlo; Xushan Wang; Beverly A Heinz; Eric S Nisenbaum; Thomas C Britton; Filippo Drago; Maria Angela Sortino; Agata Copani; Ferdinando Nicoletti Journal: Mol Pharmacol Date: 2010-12-15 Impact factor: 4.436
Authors: Chengfei Liu; Wei Lou; Yezi Zhu; Nagalakshmi Nadiminty; Chad T Schwartz; Christopher P Evans; Allen C Gao Journal: Clin Cancer Res Date: 2014-04-16 Impact factor: 12.531
Authors: Lucy M Hinder; Kelli M Sas; Phillipe D O'Brien; Carey Backus; Pradeep Kayampilly; John M Hayes; Cheng-Mao Lin; Hongyu Zhang; Sumathi Shanmugam; Amy E Rumora; Steven F Abcouwer; Frank C Brosius; Subramaniam Pennathur; Eva L Feldman Journal: Sci Rep Date: 2019-01-29 Impact factor: 4.379
Authors: Hiral A Bhagat; Sarah A Compton; David L Musso; Christopher P Laudeman; Kimberly M P Jackson; Na Young Yi; Lidia S Nierobisz; Lawrence Forsberg; Jay E Brenman; Jonathan Z Sexton Journal: PLoS One Date: 2018-10-25 Impact factor: 3.240
Authors: Jens Hagenow; Stefanie Hagenow; Kathrin Grau; Mohammad Khanfar; Lena Hefke; Ewgenij Proschak; Holger Stark Journal: Drug Des Devel Ther Date: 2020-01-28 Impact factor: 4.162